U.S. Markets close in 5 hrs 1 min

Microbot Medical Inc. (MBOT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.79-0.35 (-4.30%)
As of 10:56AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.14
Open8.06
Bid7.78 x 1400
Ask7.85 x 800
Day's Range7.69 - 8.22
52 Week Range4.30 - 20.15
Volume114,655
Avg. Volume173,684
Market Cap55.372M
Beta (5Y Monthly)5.14
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • Microbot Medical Secures Patents in Multiple Global Jurisdictions
    GlobeNewswire

    Microbot Medical Secures Patents in Multiple Global Jurisdictions

    HINGHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company’s continued execution of expanding and protecting its Intellectual Property (IP) portfolio. The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide. “As we continue to make progress on the development, clinical and regulatory fronts, it is encouraging that we are also achieving our goals to broaden the protection of our novel technologies,” commented Harel Gadot, CEO, President and Chairman. “Strengthening our IP portfolio is a critical component of Microbot’s strategy for facilitating product evolution and maximizing future commercial opportunities.”The U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance 684 pertaining to the Company’s Self-Cleaning Shunt (SCS) device. The allowed patent application is a Continuation of a patent, issued on July 19, 2016, and covers a device for mitigating occlusion in an implantable catheter. The claims are directed to a device comprising a tube having at least one drainage opening disposed in its wall and configured for implantation within a body cavity, further comprising a cleaning element having at least one cleaning protrusion extending into the opening and configured to move within the opening.Additionally, the European Patent Office (EPO) granted an EP Patent covering the Company’s guidewire technology for use with endo-luminal interventions, and related to the Company’s LIBERTYTM development. This is the second European patent granted for this unique technology and extends protection to include the device’s current development, having a double guidewire comprising a first hollow guidewire and a second guidewire deployed within the first guidewire, and an adjuster mechanism operable to displace the second guidewire longitudinally relative to the first guidewire between at least three states.About Microbot MedicalMicrobot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.Safe HarborStatements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTYTM, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.Investor Contact: Michael Polyviou EVC Group mpolyviou@evcgroup.com 732-933-2754

  • Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference
    GlobeNewswire

    Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference

    Webcast to be Held on Thursday November 12th at 2:00pm ET HINGHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that Harel Gadot, the Company’s CEO, President and Chairman, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright 6th Annual Israel Conference, on November 12, 2020 at 2:00pm ET. In addition to the presentation, the conference will feature virtual one-on-one meetings with Microbot Medical’s executives and institutional investors are invited to request meeting times at meetings@hcwco.com.“Our team has made significant progress, and we will continue to leverage these developments toward a clear clinical and regulatory path to future commercialization,” commented Mr. Gadot. “These reinforce our vision, commitment, and dedication and I am excited to share the Microbot story and highlight our achievements with investors.”A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the ‘Investors’ section, under ‘Presentation + Resources’ of the Company’s website at www.microbotmedical.com.About Microbot MedicalMicrobot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.Safe HarborStatements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.Investor Contact: Michael Polyviou EVC Group mpolyviou@evcgroup.com 732-933-2754

  • GlobeNewswire

    Microbot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis

    HINGHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 15/592,227, which pertains to a device for reducing dialysis shunt stenosis. The allowed patent application is a Continuation of Patent No. 9,675,748, which was issued on June 13, 2017. “This latest patent allowance demonstrates the continued solid execution of our IP portfolio strategy,” commented Harel Gadot, Chief Executive Officer, President and Chairman. “Expanding and protecting our innovative technologies remains a primary objective and we intend to be proactive to ensure a sustainable, competitive advantage for our products.”The allowed patent application covers a system for reducing venous stenosis associated with the use of hemodialysis shunts. A clearing device is inserted into the blood vessel through a first needle bore, while dialyzed blood is returned into the blood vessel through a second needle bore. The clearing device can be actuated from externally to the patient’s body. The clearing device is adapted to move autonomously, and it may be an autonomous crawling device, such as the Company’s TipCat™ device, which is based on a series of sequentially inflatable chambers. This allowance adds an additional layer of protection beyond the current IP protected applications of Microbot's TipCat™ and ViRob™ platforms.Globally, the Company now has a total of 39 issued/allowed patents and 23 patent applications pending worldwide.About Microbot MedicalMicrobot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.Safe HarborStatements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.Investor Contact: Michael Polyviou EVC Group mpolyviou@evcgroup.com 732-933-2754